Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Icecure Medical ( (ICCM) ) has shared an update.
On March 19, 2026, IceCure Medical appointed veteran finance executive Meir Peleg as its new Chief Financial Officer, with his tenure set to begin on May 17, 2026, bolstering the company’s leadership as it reports strong commercial momentum for its ProSense® cryoablation system following recent U.S. regulatory clearance and professional endorsement in low-risk breast cancer. IceCure also outlined leadership changes in technology and clinical strategy, including the planned second-quarter 2026 appointment of breast surgical oncologist Dr. Richard Fine as Medical Director to lead breast indications and the April 12, 2026 departure of Vice President of R&D and Engineering Naum Muchnik, as the company initiates a search for a new Chief Technology Officer.
The most recent analyst rating on (ICCM) stock is a Hold with a $0.61 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
The score is held down primarily by weak financial performance (large ongoing losses, significant cash burn, and shrinking equity), with limited valuation support due to negative earnings. Offsetting this, the latest earnings call points to improving commercial prospects and multiple adoption catalysts (FDA clearance, society endorsement, planned salesforce expansion), while technicals remain weak/neutral.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical Ltd. is an Israel-based medical device company that develops and markets minimally invasive, liquid-nitrogen-based cryoablation systems for the destruction of benign and cancerous tumors. Its flagship ProSense® system, cleared and approved in markets including the U.S., Europe and Asia, targets breast, kidney, bone and lung cancers and has U.S. marketing authorization for local treatment of low-risk breast cancer in women aged 70 and above.
Average Trading Volume: 288,190
Technical Sentiment Signal: Sell
Current Market Cap: $43.79M
See more data about ICCM stock on TipRanks’ Stock Analysis page.